지혈 밸브 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The hemostasis valve market generated USD 193.75 million in 2025 and is projected to reach USD 250.83 million by 2030, reflecting a 5.30% CAGR.

Growth accompanies a 20.9% jump in interventional cardiology procedure volumes reported by Boston Scientific in Q1 2025, underscoring robust device utilization. The continuing transition from femoral to radial access drives demand for low-profile valves that maintain seal integrity with smaller French sizes. Product innovation now centers on single-handed operation and pressure-responsive "smart" valves able to relay real-time intraluminal pressure. Regulatory costs tied to EU-MDR re-certification and raw-material shortages of medical-grade silicone pose cost pressures, yet rising adoption of same-day discharge protocols in ambulatory settings offsets these hurdles through higher procedural throughput.

Global Hemostasis Valve Market Trends and Insights

Surging Volume of Interventional Cardiology & Radiology Procedures

Q1 2025 results showed a 20.9% year-over-year sales rise for Boston Scientific attributable to higher catheterization activity. Complex procedures require multiple device exchanges, elevating the need for reliable hemostasis valves that minimize blood loss. Operators now favor premium seals for high-risk neuro-interventions, where middle meningeal artery embolization volumes could hit 79,483 cases by 2029. Increased procedure counts translate directly into recurring demand for disposable valves. In addition, supportive reimbursement schemes in the United States continue to reward radial access, sustaining device utilization. These factors collectively add 1.8 percentage points to the anticipated CAGR.

Rising Global Burden of Cardiovascular & Chronic Metabolic Diseases

Age-standardized ischemic heart disease prevalence remains high even as mortality declines, leading to more repeat interventions over a patient's lifetime. Asia already records 722.45 heart-failure cases per 100,000 population, intensifying catheter-based therapy needs. A growing hypertensive population further drives electrophysiology volumes, pushing adoption of specialized hemostasis solutions. Procedure repetitions for chronic disease monitoring secure a durable growth runway. Lower-cost disposable kits aimed at emerging markets broaden access. The combined effect raises the growth trajectory by 1.2 percentage points.

Operational Complexity & Supervision Challenges in High-Throughput Cath-Labs

Physicians now execute more than 100 procedures each year, but case complexity climbs, raising staff fatigue and radiation exposure concerns. Workforce shortages oblige tailored education programs to sustain competencies. Real-time perception systems promise automation yet remain experimental. Maintaining diverse valve inventories for varied sheath sizes complicates logistics and can delay procedures. Collectively, these operational hurdles shave 0.7 percentage points off expected CAGR growth.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Adoption of Minimally-Invasive Endovascular Surgeries
2. Rapid Shift to Radial Access & Lower-French Devices
3. Availability of Alternative Vascular Closure Technologies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hemostasis Valve Y-Connectors retained a 43.35% hemostasis valve market share in 2024, confirming their entrenched role in dual-port access for diagnostic angiography. The segment's stability underpins a sizable installed base that ensures repeat purchases. Operator feedback, however, increasingly favors single-handed manipulation to cut exchange times, triggering rapid adoption of One-Handed Hemostasis Valves that post a 9.25% CAGR through 2030. The shift influences procurement policies at teaching hospitals where efficiency metrics are closely tracked.

One-Handed valves incorporate cross-slit seals that maintain integrity at elevated pressures, exemplified by the WATCHDOG system. Double Y-Connectors target niche procedures needing simultaneous guidewire and microcatheter access, whereas Integrated Extension-Line valves gain momentum for chronic total occlusion work. Push-Pull designs survive in legacy setups but face cannibalization. Material advances, including high-durometer silicone, reduce valve fatigue during lengthy rotational atherectomy, further boosting adoption among high-volume centers keen on workflow streamlining.

The Hemostasis Valve Market Report is Segmented by Product Type (Hemostasis Valve Y-Connectors, Double Y-Connector Valves, One-Handed Hemostasis Valves, and More), Application (Angiography, Angioplasty, and More), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America captured 37.82% of the hemostasis valve market in 2024, bolstered by high procedural volumes and advanced reimbursement structures. Extensive radial adoption combined with an aging population maintains steady unit demand. Europe follows with consistent spending, although EU-MDR compliance introduces cost headwinds that may temper near-term growth.

Asia-Pacific is the standout, poised for an 8.31% CAGR as domestic manufacturers scale production of cost-effective valves aligned with regional price sensitivities. Government-funded cath-lab rollouts in Indonesia and the Philippines emphasize day-case capacity, creating demand for durable valves that tolerate sterilization cycles. Japan and South Korea continue to set quality benchmarks, spurring local suppliers to adopt high-precision molding technologies. The hemostasis valve market size for Asia-Pacific is therefore projected to close the decade at roughly USD 81 million, representing meaningful share gains.

The Middle East and Africa show latent potential, hinged on national cardiac-center programs emerging in Saudi Arabia and the United Arab Emirates. South America gradually advances as Brazil lifts capital-equipment import barriers, yet currency volatility moderates momentum. Collectively, these regions provide diversification opportunities for multinationals hedging against saturated developed markets.

1. Boston Scientific
2. Merit Medical Systems
3. Teleflex
4. Terumo
5. Freudenberg
6. Argon Medical Devices
7. B. Braun
8. Antmed
9. Abbott Laboratories
10. DeRoyal Industries
11. Minivalve International
12. Asahi Intecc Co. Ltd.
13. Cook Group
14. Medtronic
15. Nipro
16. Qosina Corp.
17. Galt Medical Corp.
18. Becton Dickinson & Co.
19. Cardionovum
20. Nordson Medical
21. Smiths Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Surging Volume of Interventional Cardiology & Radiology Procedures
  • 4.2.2 Rising Global Burden of Cardiovascular & Chronic Metabolic Diseases
  • 4.2.3 Growing Adoption of Minimally-Invasive Endovascular Surgeries
  • 4.2.4 Rapid Shift To Radial Access & Lower-French Devices Boosting Demand For Low-Profile Valves
  • 4.2.5 Proliferation of Day-Case Cath-Labs In Emerging Economies Requiring Reusable Kits
  • 4.2.6 Commercialization of Pressure-Responsive Smart Hemostasis Valves Enabling Real-Time Monitoring
• 4.3 Market Restraints
  • 4.3.1 Operational Complexity & Supervision Challenges In High-Throughput Cath-Labs
  • 4.3.2 Availability of Alternative Vascular Closure Technologies
  • 4.3.3 Volatile Supply of Medical-Grade Silicone & Polycarbonate Resins
  • 4.3.4 Cost Escalation Linked To EU-MDR Class-Iib/III Re-Certification
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Hemostasis Valve Y-Connectors
  • 5.1.2 Double Y-Connector Valves
  • 5.1.3 One-Handed Hemostasis Valves
  • 5.1.4 Integrated Extension-Line Valves
  • 5.1.5 Push-Pull Hemostasis Valves
  • 5.1.6 Others
• 5.2 By Application
  • 5.2.1 Angiography
  • 5.2.2 Angioplasty
  • 5.2.3 Electrophysiology Procedures
  • 5.2.4 Neuro-interventional Procedures
  • 5.2.5 Peripheral Vascular Interventions
  • 5.2.6 Other Applications
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Catheterization Laboratories
  • 5.3.4 Specialty Clinics
  • 5.3.5 Other End Users
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Boston Scientific Corporation
  • 6.3.2 Merit Medical Systems
  • 6.3.3 Teleflex Incorporated
  • 6.3.4 Terumo Corporation
  • 6.3.5 Freudenberg Medical
  • 6.3.6 Argon Medical Devices
  • 6.3.7 B. Braun Melsungen AG
  • 6.3.8 Antmed Corporation
  • 6.3.9 Abbott Laboratories
  • 6.3.10 DeRoyal Industries Inc.
  • 6.3.11 Minivalve International
  • 6.3.12 Asahi Intecc Co. Ltd.
  • 6.3.13 Cook Medical
  • 6.3.14 Medtronic plc
  • 6.3.15 Nipro Corporation
  • 6.3.16 Qosina Corp.
  • 6.3.17 Galt Medical Corp.
  • 6.3.18 Becton Dickinson & Co.
  • 6.3.19 Cardionovum GmbH
  • 6.3.20 Nordson Medical
  • 6.3.21 Smiths Medical (ICU Medical)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment